Matthew Gallitto
Overview
Explore the profile of Matthew Gallitto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gallitto M, Zhang X, De Los Santos G, Wei H, Fernandez E, Duan S, et al.
Neuro Oncol
. 2024 Oct;
27(3):795-810.
PMID: 39394920
Background: Diffuse midline glioma (DMG) is the most aggressive primary brain tumor in children. All previous studies examining the role of systemic agents have failed to demonstrate a survival benefit;...
2.
Lee A, Pasetsky J, Lavrova E, Wang Y, Sedor G, Li F, et al.
Clin Transl Radiat Oncol
. 2024 Aug;
48:100813.
PMID: 39149753
Purpose/objectives: Retrospective analysis suggests that dose escalation to a biologically effective dose of more than 70 Gy may improve overall survival in patients with pancreatic ductal adenocarcinoma (PDAC), but such...
3.
Zhang X, Duan S, Apostolou P, Wu X, Watanabe J, Gallitto M, et al.
Cancer Discov
. 2024 May;
14(9):1732-1754.
PMID: 38767413
High-grade gliomas (HGG) are deadly diseases for both adult and pediatric patients. Recently, it has been shown that neuronal activity promotes the progression of multiple subgroups of HGG. However, epigenetic...
4.
Gallitto M, Sedor G, Lee A, Pasetsky J, Kinslow C, De Los Santos G, et al.
Int J Radiat Oncol Biol Phys
. 2024 Apr;
120(3):730-737.
PMID: 38641234
Purpose: The role of stereotactic radiosurgery (SRS) in the management of grade 2 and 3 meningiomas is not well elucidated. Unfortunately, local recurrence rates are high, and guidelines for management...
5.
Fernandez E, Tomassoni L, Zhang X, Wang J, Obradovic A, Laise P, et al.
bioRxiv
. 2024 Apr;
PMID: 38559080
Diffuse Midline Gliomas (DMGs) are universally fatal, primarily pediatric malignancies affecting the midline structures of the central nervous system. Despite decades of clinical trials, treatment remains limited to palliative radiation...
6.
Tazhibi M, McQuillan N, Wei H, Gallitto M, Bendau E, Webster Carrion A, et al.
J Transl Med
. 2024 Mar;
22(1):320.
PMID: 38555449
Background: Diffuse midline glioma (DMG) is a pediatric tumor with dismal prognosis. Systemic strategies have been unsuccessful and radiotherapy (RT) remains the standard-of-care. A central impediment to treatment is the...
7.
Gallitto M, Pan P, Chan M, Milano M, Wang T
Neuro Oncol
. 2024 Mar;
26(12 Suppl 2):S66-S75.
PMID: 38437664
The clinical efficacy and relative tolerability of adverse effects of immune checkpoint immunotherapy have led to its increasingly routine use in the management of multiple advanced solid malignancies. Radiation therapy...
8.
Padilla O, Minns H, Wei H, Fan W, Webster-Carrion A, Tazhibi M, et al.
Int J Radiat Oncol Biol Phys
. 2024 Feb;
119(4):1248-1260.
PMID: 38364947
Purpose: Diffuse midline glioma (DMG) is a fatal tumor traditionally treated with radiation therapy (RT) and previously characterized as having a noninflammatory tumor immune microenvironment (TIME). FLASH is a novel...
9.
Rayn K, Deutsch I, Jeffers B, Lee A, Lavrova E, Gallitto M, et al.
Adv Radiat Oncol
. 2024 Feb;
9(3):101408.
PMID: 38304110
Purpose: To maximize the therapeutic ratio, it is important to identify adverse prognostic features in men with prostate cancer, especially among those with intermediate risk disease, which represents a heterogeneous...
10.
Ishak E, Gallitto M, Golub J, Sisti M, Wang T
Pract Radiat Oncol
. 2024 Jan;
14(3):212-215.
PMID: 38211694
The cochlear apparatus is one of the major organs at risk when considering radiation therapy (RT) for brain, head, and neck tumors. Radiation oncologists currently consider mean dose constraints of...